Designation of Ceritinib (Zykadia) as an orphan drug by Novartis Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate therapeutic goods, including medicines, medical devices, and blood. The Act was introduced to address the need for a robust regulatory framework to ensure the safety, quality, and efficacy of therapeutic goods available to the public. One specific objective outlined in the Act is to provide incentives for the development of orphan drugs, which are medicines intended for the treatment of rare conditions. In line with this objective, the Therapeutic Goods Administration (TGA) has the authority to designate certain drugs as orphan drugs, facilitating their development and availability. In September 2014, the TGA designated Ceritinib (ZYKADIA) as an orphan drug for the treatment of non-small cell lung cancer that is anaplastic lymphoma kinase (ALK)-positive, aiming to support the development of treatments for this rare condition and improve patient outcomes.

Scope and Application

The designation of Ceritinib (ZYKADIA) as an orphan drug under the Therapeutic Goods Act 1989 applies specifically to the pharmaceutical product Ceritinib, marketed under the name ZYKADIA, and pertains to its use in the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)–positive. This designation is applicable to Novartis Pharmaceuticals Australia Pty Ltd, the sponsor of the drug. The scope of the legislation ensures that Ceritinib (ZYKADIA) is recognised for its intended therapeutic purpose and aids in facilitating the development and availability of treatments for rare diseases. The geographic and jurisdictional reach of this Act is nationwide, aligning with the Commonwealth's regulatory framework over therapeutic goods. There are no explicit exclusions, exemptions, or thresholds outlined in this specific gazette, but the broader Therapeutic Goods Act and Regulations may include various conditions and requirements governing the approval, distribution, and usage of therapeutic goods in Australia. The application and interpretation of this Act may be further refined or expanded through subordinate instruments issued under the authority of the Therapeutic Goods Administration.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) facilitates the regulation of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. Section 16J of the Therapeutic Goods Regulations 1990 (the Regulations) allows for the designation of certain drugs as orphan drugs, which is a mechanism to encourage the development of treatments for rare diseases or conditions. In this case, Section 16J(2) of the Regulations empowers a Delegate of the Secretary to designate a particular therapeutic substance as an orphan drug. Specifically, Dr. Anthony Gill, acting in his capacity as a Delegate, has designated Ceritinib (ZYKADIA) as an orphan drug for the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive, effective from 1 September 2014. This designation imposes certain obligations on the parties involved, particularly the sponsor of the drug, Novartis Pharmaceuticals Australia Pty Ltd. The sponsor must ensure that Ceritinib (ZYKADIA) meets all the criteria and requirements for being an orphan drug as outlined under the Act and the Regulations. This includes maintaining records and providing data that demonstrate the drug's suitability for the specified condition and ensuring that the drug is manufactured and marketed in compliance with regulatory standards. The sponsor is also responsible for any updates or changes in the drug's status, ensuring ongoing compliance with the legislative framework. Failure to adhere to the provisions of the Act and the Regulations can result in various civil and criminal consequences. For instance, if the sponsor does not comply with the requirements for orphan drug designation or if the drug does not meet the criteria for such designation, it could result in enforcement actions. Under the Act, there are potential penalties, including fines and, in severe cases, criminal charges for individuals. The maximum penalties for offences under the Act can be significant, with fines reaching up to $1,650,000 for corporations and $330,000 for individuals, depending on the severity and nature of the breach. Additionally, persistent or egregious violations may lead to prosecution, further highlighting the importance of compliance with the legislative requirements.